Categories
Markets

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST Stock – (NASDAQ: ACST) is providing an update on the use

ACST
-1.84%
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the use of its “at-the market” equity providing plan.

As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering program under which Acasti might issue as well as market from time to time the everyday shares of its having an aggregate offering price of up to $75 million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 zillion. The ATM Shares had been offered at prevailing market costs averaging US$1.0747 per share. No securities had been sold in the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and outstanding as of March 5, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with more freedom in its continuous review process to enjoy and evaluate strategic options.

Approximately Acasti – ACST Stock

Acasti is a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescription drugs using OM3 fatty acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical proof of efficacy as well as safety in lowering triglycerides in individuals with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for people with severe HTG.

Forward Looking Statements – ACST Stock

Statements in this press release that aren’t statements of current or historical fact constitute “forward looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking assertions include known and unknown risks, uncertainties, along with other unknown variables that may cause the particular results of Acasti to be materially different from historical success or from any later outcomes expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, readers are urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other related expressions to be forward-looking and uncertain. People are cautioned not to place undue reliance on these forward-looking statements, which speak just as of the day of this particular press release. Forward-looking statements in that press release include, but are not limited to, info or statements about Acasti’s strategy, succeeding operations as well as its review of strategic options.

The forward-looking assertions found in this press release are expressly qualified in the entirety of theirs by this cautionary statement, the “Special Note Regarding Forward-Looking Statements” section found in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. All forward-looking statements in that press release are manufactured as of the particular date of this press release.

ACST Stock – Acasti doesn’t undertake to upgrade some such forward-looking statements whether as a consequence of new information, future events or even otherwise, except as called for by law. The forward looking statements contained herein are also subject typically to risks and assumptions and uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is providing an update on the use

Leave a Reply

Your email address will not be published. Required fields are marked *